Massachusetts pharmacy recalls products
BOSTON — A Massachusetts pharmacy issued a voluntary recall on Monday of some of its sterile compounding products because “foreign matter” was found in drug vials during an unannounced inspection by state and federal officials.
Pallimed Solutions Inc. of Woburn was ordered by the state board of pharmacy to stop all sterile compounding activities until further notice.
Most of the recalled items were used to prepare erectile dysfunction treatments for patients who have difficulty taking drugs orally. The company said fewer than 800 patients were involved.
The company described the recall as a precautionary measure and said it had received no reports of any illnesses or injuries. It also said it would continue with nonsterile compounding.
The Massachusetts Department of Public Health said it requested the recall after a joint inspection on Friday by the state pharmacy board and the Food and Drug Administration.
“The cease and desist was issued after foreign matter was observed in vials of injectable drugs,” the Department of Public Health said.
Pallimed was ordered to place all its compounded sterile products into quarantine while the investigation continued.
The company said there was no indication the products were tainted or unsafe. The state said there were no reports of any patient harm.
A message was left with the FDA.
Massachusetts stepped up unannounced inspections of compounding pharmacies after a deadly fungal meningitis outbreak last year was linked to an injectable steroid produced at another Massachusetts company, New England Compounding Center.
That outbreak was responsible for 720 illnesses in 20 states, including 48 deaths, according to the most recent update from the Centers for Disease Control and Prevention.
Framingham-based NECC ceased operations in October and surrendered its license to the Massachusetts board.
Pallimed Solutions is a 7-year-old company that does business as Pallimed Pharmacy and has about 15 employees, according to its website. It said it regretted any impact on customers and that patient safety was its top priority.
“By undertaking this recall action, Pallimed will move forward to ensure that our products always meet the highest standards of safety and customer expectations,” the company said in its statement.
On Nov. 27, the state ordered Pallimed to temporarily stop production of sildenafil citrate — the active ingredient in Viagra — for human use after inspectors found it had been prepared with improper components. The company said those issues were administrative in nature and had been resolved, and Monday's announcement was unrelated.
The state said the earlier order was still in place, pending the board's acceptance of a corrective plan.
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
- U.S., Cuba to announce plan to open embassies
- Charter lapses for Export-Import Bank; conservatives vow to block revival in House
- NSA resumes collection of phone data
- White House intruders beware: Spikes planned
- Emails from Clinton’s first year as secretary of State out
- Ten Commandments monument orderered removed from Oklahoma Capitol grounds
- FDA review of OxyContin abuse-deterrent version put on hold by maker
- Supreme Court to take up mandated dues for public employees unions in next term
- Nike’s chairman plans to step aside
- Counties defy same-sex marriage ruling
- New York prison chief, 11 employees put on leave in escape